Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ORCL -9%, HAE -2% (guidance), CASY -1%, JCI -0.9%
Other news:
- ATHA -9.8% (Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton)
- CBUS -7% (prices 2106723 Class A shares at $9.00 per share)
- SBOW -6.5% (prices secondary offering of 2.2 mln shares of common stock)
- KNTK -6.4% (prices secondary offering of 6.5 mln shares of common stock at $31.50 per share)
- HAS -5.5% (to reduce workforce by nearly 20%)
- SNCY -4.8% (prices secondary offering of 4 mln shares of its common stock by an affiliate of certain investment funds managed by affiliates of Apollo Global Management) GO -4% (CFO stepping down; reaffirms Q4 guidance)
- MAT -3% (trading in sympathy with HAS)
- LCID -2.9% (CFO departing)
- LQDA -2.7% (prices offering of 3491620 shares of common stock at a public offering price of $7.16 for total gross proceeds of approximately $25.0 million; also provides United Therapeutics Corporation (UTHR) patent update)
- AMRC -2.5% (selected in Hawaiian Electric Company's clean energy initiative)
- IOSP -2% (acquires QCP Quimica Geral)
- GPOR -1.8% (prices block trade by selling shareholders of 653464 Shares of Common Stock for gross proceeds of $84.2 mln)
- LPTX -1.5% (to present new data)
Analyst comments:
- GPRO -5.3% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- AMCX -2.1% (downgraded to Neutral from Buy at Seaport Research Partners)
- ABNB -1.9% (downgraded to Underweight from Equal Weight at Barclays)
- A -1.5% (downgraded to Neutral from Buy at BofA Securities)
- AJG -1% (downgraded to Mkt Perform from Strong Buy at Raymond James)
- EXPE -0.9% (downgraded to Equal Weight from Overweight at Barclays)